Early intensive therapy for clinical remission of active IgA nephropathy: a three-year follow-up study.
To achieve clinical remission, intensive therapy in active IgA nephropathy was conducted on a trial basis. Forty-five patients with active IgAN in which cellular crescents were present were divided into two groups. The patients in one group (Group A, N = 19) were treated with a combined regimen of steroid pulse, cyclophosphamide (4 months), dipyridamole (36 months) and warfarin. The patients in the other group (Group B, N = 26) were treated with tonsillectomy in addition to the same regimen as Group A. Three years after the initiation of treatment, proteinuria and hematuria had significantly decreased in both groups, and the renal function in Group B was significantly improved. Remission of proteinuria and hematuria was achieved in five patients (26.3%) and eight patients (42.1%), respectively, in Group A, and 14 patients (53.8%) and 20 patients (76.9%), respectively, in Group B. These results indicate that early intensive therapy combined with tonsillectomy in active IgAN is potentially of great benefit from both the medical and socioeconomic points of view.
Hotta
O
O
Department of Nephrology, Sendai Shakaihoken Hospital, Japan.
Taguma
Y
Y
Kurosawa
K
K
Sudo
K
K
Suzuki
K
K
Horigome
I
I
D000293:Adolescent; D000328:Adult; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004176:Dipyridamole / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005922:Glomerulonephritis, IGA / Q000150:complications / Q000628:therapy*; D006417:Hematuria / Q000209:etiology / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D011507:Proteinuria / Q000209:etiology / Q000628:therapy; D012074:Remission Induction; D014068:Tonsillectomy; D014859:Warfarin / Q000008:administration & dosage*
D014859:Warfarin; D004176:Dipyridamole; D003520:Cyclophosphamide